Aura Biosciences
AURA
57 hedge funds and large institutions have $233M invested in Aura Biosciences in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
16% more funds holding
Funds holding: 49 → 57 (+8)
0.27% more ownership
Funds ownership: 66.06% → 66.32% (+0.27%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less capital invested
Capital invested by funds: $250M → $233M (-$17.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6M |
| 2 |
Citigroup
New York
|
+$3.85M |
| 3 |
BlackRock
New York
|
+$2.89M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.85M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$4.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.86M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.44M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.38M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$297K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Legal & General Group
London,
United Kingdom
| $26.5K | +$6.18K | +595 | +26% |
|
|
AIP
52
Ameritas Investment Partners
Lincoln,
Nebraska
| $12.8K | – | – | – |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| $12K | -$14.1K | -1,358 | -51% |
|
|
MLICM
54
Metropolitan Life Insurance Company (MetLife)
New York
| $10.5K | -$1.54K | -148 | -12% |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| $10K | -$25.5K | -2,459 | -70% |
|
56
UBS Group
Zurich,
Switzerland
| $5.06K | -$5.81K | -559 | -51% |
|
|
EI
57
Ellevest Inc
New York
| $121 | +$135 | +13 | New |
|
|
AG
58
Artal Group
Luxembourg
| – | -$4.3M | -410,000 | Closed |
|
|
MIM
59
Monashee Investment Management
Boston,
Massachusetts
| – | -$1.38M | -131,640 | Closed |
|
60
Alyeska Investment Group
Chicago,
Illinois
| – | -$225K | -21,456 | Closed |
|
61
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$274K | -19,429 | Closed |
|
|
CH
62
CVI Holdings
Wilmington,
Delaware
| – | -$132K | -12,592 | Closed |
|
|
CS
63
Credit Suisse
Zurich,
Switzerland
| – | -$11 | -1 | Closed |
|
AURA Hedge Fund Activity: Q1 2023 in Review
57 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q1 2023, worth a combined $233M — down 7% from $250M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AURA positions and 6 closed out — a net gain of 8 holders — while 24 added to existing stakes and 12 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $6M. The largest seller was Artal Group, exiting entirely with an estimated $4.3M sold.
- 57 institutional investors held Aura Biosciences (AURA) as of Q1 2023, up from 49 in Q4 2022.
- Funds reported $233M of Aura Biosciences stock for Q1 2023, down 7% quarter-over-quarter.
- 14 funds opened new Aura Biosciences positions in Q1 2023 and 6 closed out, a net change of +8 holders.
- The largest Aura Biosciences buyer in Q1 2023 was Adage Capital Partners, an estimated $6M added.
- The largest Aura Biosciences seller in Q1 2023 was Artal Group, an estimated $4.3M sold.
Based on aggregated 13F filings for Q1 2023.